Advertisement BioElectronics announces clinical study of menstrual pain therapy product - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BioElectronics announces clinical study of menstrual pain therapy product

BioElectronics, a developer of inexpensive, disposable drug-free anti-inflammatory devices, has announced the organization of a new clinical study to demonstrate the efficacy of its Allay menstrual pain therapy product.

The randomized double-blind, placebo and positive controlled trial involving approximately 120 adult female women began in early March 2009 with data expected in approximately 60 days.

In an initial pilot study, 23 female patients with problematic menstrual issues used the Allay product continuously for five days when the onset of their menstrual period was evident and achieved an overall pain reduction on a daily basis of between 31% and 73%, said BioElectronics.